Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy

被引:35
作者
Micheloud, D.
Nuno, L.
Rodriguez-Mahou, M.
Sanchez-Ramon, S.
Ortega, M. C.
Aguaron, A.
Junco, E.
Carbone, J.
Fernandez-Cruz, E.
Carreno, L.
Lopez-Longo, F. J.
机构
[1] Univ Gen Hosp Gregorio Maranon, Dept Reumatol, Madrid 28007, Spain
[2] Univ Gen Hosp Gregorio Maranon, Dept Immunol, Madrid 28007, Spain
[3] Univ Gen Hosp Gregorio Maranon, Dept Gynecol & Obstet, Madrid 28007, Spain
[4] Univ Gen Hosp Gregorio Maranon, Dept Nephrol, Madrid 28007, Spain
关键词
systemic lupus erytematosus; pregnancy; etanercept; intravenous gammaglobulin and plasmapheresis;
D O I
10.1177/0961203306070970
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report one case of pregnancy-onset severe diffuse proliferative nephritis in a patient with systemic lupus erythematosus (SLE), who was successfully treated with a combination of anti-tumour necrosis factor (TNF)-alpha, plasmapheresis and high-dose intravenous gammaglobulin. No flares were observed either in clinical symptoms or in laboratory examinations during pregnancy or after delivery. Her autoantibodies except fluorescent anti-nuclear antibodies were negative. We suggest that a combination of anti-TNF-alpha, plasmapheresis and high-dose intravenous gammaglobulin may be a safe and effective therapy for pregnant patients suffering severe lupus nephritis.
引用
收藏
页码:881 / 885
页数:5
相关论文
共 40 条
[1]   Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins [J].
Arahata, H ;
Migita, K ;
Izumoto, H ;
Miyashita, T ;
Munakata, H ;
Nakamura, H ;
Tominaga, M ;
Origuchi, T ;
Kawabe, Y ;
Hida, A ;
Taguchi, T ;
Eguchi, K .
CLINICAL RHEUMATOLOGY, 1999, 18 (01) :77-81
[2]   Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus -: An open-label study [J].
Aringer, M ;
Graninger, WB ;
Steiner, GN ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2004, 50 (10) :3161-3169
[3]   Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis [J].
Boletis, JN ;
Ioannidis, JPA ;
Boki, KA ;
Moutsopoulos, HM .
LANCET, 1999, 354 (9178) :569-570
[4]  
CARRENO L, 2005, THERAPEUTICAL APHERE, P102
[5]  
Carreno Luis, 2002, Paediatr Drugs, V4, P241, DOI 10.2165/00148581-200204040-00004
[6]   Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Mejía, JC ;
Aydintug, AC ;
Chwalinska-Sadowska, H ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Valen, M ;
Mathieu, A ;
Houssiau, FD ;
Caro, N ;
Alba, P ;
Ramos-Casals, M ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 2003, 82 (05) :299-308
[7]   Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus:: a prospective study of 103 pregnancies [J].
Cortés-Hernández, J ;
Ordi-Ros, J ;
Paredes, F ;
Casellas, M ;
Castillo, F ;
Vilardell-Tarres, M .
RHEUMATOLOGY, 2002, 41 (06) :643-650
[8]   Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia [J].
Dechend, R ;
Gratze, P ;
Wallukat, G ;
Shagdarsuren, E ;
Plehm, R ;
Bräsen, JH ;
Fiebeler, A ;
Schneider, W ;
Caluwaerts, S ;
Vercruysse, L ;
Pijnenborg, R ;
Luft, FC ;
Müller, DN .
HYPERTENSION, 2005, 45 (04) :742-746
[9]   Activating auto-antibodies against the AT1 receptor in preeclampsia [J].
Dechend, R ;
Müller, DN ;
Wallukat, G ;
Homuth, V ;
Krause, M ;
Dudenhausen, J ;
Luft, FC .
AUTOIMMUNITY REVIEWS, 2005, 4 (01) :61-65
[10]   Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus [J].
DePita, O ;
Bellucci, AM ;
Ruffelli, M ;
Girardelli, CR ;
Puddu, P .
LUPUS, 1997, 6 (04) :415-417